Mylan

September 27, 2019October 16, 2019

Mylan Launches Generic Version of Faslodex Injection in the US

News

The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company ... Read more

December 4, 2017December 4, 2017

FDA Approves Ogivri, Biosimilar to Herceptin, to Treat HER2+ Breast Cancer

News

HER2-positive breast cancer patients in the U.S. will have the possibility of being treated with a biosimilar to Herceptin (trastuzumab), following the approval of Ogivri (trastuzumab-dkst) as a more affordable ... Read more

December 7, 2016December 7, 2016

Biosimilar Seen to Match Herceptin in Treating Advanced Breast Cancer in Clinical Trial

News

A Phase 3 clinical trial comparing Mylan’s proposed biosimilar trastuzumab with the original Herceptin (trastuzumab) found no difference between the drugs in effectiveness or safety, suggesting that the biosimilar may be a ... Read more